[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642691":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":46,"responsibleParty":61,"collaborators":26,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":26,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":26,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":87,"overallStatus":91,"whyStopped":26,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intranasal esketamine-dexmedetomidine","EXPERIMENTAL","Participants in this arm will receive intranasal administration of dexmedetomidine-esketamine combination.\n\nThe dosage will be calculated based on body weight (approximately 0.4 μg\u002Fkg of dexmedetomidine and 0.2 mg\u002Fkg of esketamine). The mixture of study drugs will be administered via a nasal spray device, alternating between the two nostrils every 5 minutes, until the target dose is reached.\n\nThe combination will be administered twice after chilbirth with an interval of 12 hours (2 sessions in total).",[13],"Drug: Esketamine-dexmedetomidine combination",{"label":15,"type":16,"description":17,"interventionNames":18},"Intranasal placebo","PLACEBO_COMPARATOR","Participants in this arm will receive intranasal administration of placebo (normal sline).\n\nThe dosage (volume) will be calculated based on body weight in the same way as that in the intervention group. The placebo (normal saline) will be administered via a nasal spray device, alternating between the two nostrils every 5 minutes, until the target dose is reached.\n\nThe placebo will be administered twice after childbirth with an interval of 12 hours (2 sessions in total).",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Esketamine-dexmedetomidine combination","The dosage will be calculated based on body weight (approximately 0.4 μg\u002Fkg of dexmedetomidine and 0.2 mg\u002Fkg of esketamine). The mixture of study drugs will be administered via a nasal spray device, alternating between the two nostrils every 5 minutes, until the target dose is reached. The combination will be administered twice after childbirth with an interval of 12 hours (2 sessions in total).",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Placebo","The dosage (volume) will be calculated based on body weight in the same way as that in the intervention group. The placebo (normal saline) will be administered via a nasal spray device, alternating between the two nostrils every 5 minutes, until the target dose is reached. The placebo will be administered twice after childbirth with an interval of 12 hours (2 sessions in total).",[15],[32],"Normal saline",[34],{"name":35,"affiliation":5,"role":36},"Dong-Xin Wang, MD, PhD","PRINCIPAL_INVESTIGATOR",[38,42],{"name":35,"role":39,"phone":40,"phoneExt":26,"email":41},"CONTACT","010-83572784","wangdongxin@hotmail.com",{"name":43,"role":39,"phone":44,"phoneExt":26,"email":45},"Chun-Mei Deng, MD","010-83575085","amychunmei@126.com",[47],{"facility":5,"status":26,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Beijing","Beijing Municipality","100034","China","CN",{"type":54,"coordinates":55},"Point",[56,57],116.39723,39.9075,{"lat":57,"lon":56},[60],{"name":35,"role":39,"phone":40,"phoneExt":26,"email":41},{"type":36,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Dong-Xin Wang","Professor and Chairman, Department of Anaesthesiology","100642691","phase-4-intranasal-esketamine-dexmedetomidine-combination-and-postpartum-depression-100642691",false,"NCT07639099","Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression","Impact of Intranasal Esketamine-dexmedetomidine Combination on Postpartum Depression in Parturients With Prenatal Depressive Symptoms: a Randomized, Double-blind, and Placebo-controlled Trial","Inclusion Criteria:\n\n* Pregnant women aged ≥18 years who are preparing for childbirth;\n* Positive prenatal depression screening, defined as a Patient Health Questionnaire-9 (PHQ-9) score ≥5.\n\nExclusion Criteria:\n\n* History of schizophrenia or existence of communication barriers;\n* Severe obstetric complications, including severe preeclampsia, placenta accreta, HELLP syndrome, placenta previa, placental abruption, or ASA physical status classification \\>III;\n* Contraindications to ketamine\u002Fesketamine, including refractory hypertension, severe cardiovascular disease (NYHA class ≥III), or hyperthyroidism;\n* Contraindications to dexmedetomidine, including severe bradycardia (heart rate \\\u003C50 bpm), or second-degree or higher atrioventricular block;\n* Unsuitable for intranasal administration due to nasal cavity diseases (e.g., rhinitis, nasal polyps, or nasal congestion of any cause);\n* Refusal to participate in this study or concurrent participation in another clinical trial.","FEMALE","18 Years",{"count":74,"type":75},164,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","Esketamine has rapid-onset antidepressant effects and may reduce postpartum depression in parturients with prenatal depressive symptoms. However, its adverse neuropsychiatric symptoms limits clinical application. Dexmedetomidine can alleviate these adverse symptoms and has independent antidepressant effect. This randomized, double-blind, placebo-controlled trial is designed to evaluate whether intranasal esketamine combined with dexmedetomidine can reduce the prevalence of postpartum depression in women with prenatal depressive symptoms.",[81,82,83,84,85,86],"Parturients","Depressive Symptoms","Esketamine","Dexmedetomidine","Intranasal Administration","Postpartum Depression",[81,88,83,84,89,90],"Prenatal depressive symptoms","Intranasal administration","Postpartum depression","NOT_YET_RECRUITING","2026-06-11",{"date":94,"type":95},"2026-06-15","ACTUAL",{"date":97,"type":75},"2026-06",{"date":99,"type":75},"2029-12",{"name":5,"class":6},1]